Cost-Effectiveness of Pembrolizumab With or Without Chemotherapy for Stage IV Non-Squamous NSCLC with High PD-L1 in Switzerland

被引：0

作者：

Pardo, E. ^{[1
]}

Barbier, M. ^{[2
]}

Panje, C. ^{[3
]}

Gautschi, O. ^{[4
]}

Lupatsch, J. ^{[5
]}

机构：

[1] Canton Hosp Lucerne, Med Oncol, Internal Med, Luzern, Switzerland

[2] Univ Basel, Inst Pharmaceut Med Ecpm, Basel, Switzerland

[3] Cantonal Hosp St Gallen, Radiat Oncol, St Gallen, Switzerland

[4] Canton Hosp Lucerne, Luzern, Switzerland

[5] Univ Basel, Basel, Switzerland

来源：

关键词：

cost-effectiveness; Pembrolizumab; NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P08.03

引用

页码：S992 / S992

页数：1